JP2017535583A - Gd−DOTA金属錯体のメグルミン塩を含む製剤 - Google Patents
Gd−DOTA金属錯体のメグルミン塩を含む製剤 Download PDFInfo
- Publication number
- JP2017535583A JP2017535583A JP2017528110A JP2017528110A JP2017535583A JP 2017535583 A JP2017535583 A JP 2017535583A JP 2017528110 A JP2017528110 A JP 2017528110A JP 2017528110 A JP2017528110 A JP 2017528110A JP 2017535583 A JP2017535583 A JP 2017535583A
- Authority
- JP
- Japan
- Prior art keywords
- dota
- excess
- mol
- solution
- gadolinium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- -1 Gd-DOTA metal complex Chemical class 0.000 title claims abstract description 23
- 238000009472 formulation Methods 0.000 title claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 67
- WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims abstract description 66
- 229910052688 Gadolinium Inorganic materials 0.000 claims abstract description 46
- 239000002738 chelating agent Substances 0.000 claims abstract description 38
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims abstract description 33
- GFSTXYOTEVLASN-UHFFFAOYSA-K gadoteric acid Chemical compound [Gd+3].OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 GFSTXYOTEVLASN-UHFFFAOYSA-K 0.000 claims abstract description 25
- 238000001914 filtration Methods 0.000 claims abstract description 12
- 239000002616 MRI contrast agent Substances 0.000 claims abstract description 11
- 239000000243 solution Substances 0.000 claims description 41
- 229960003194 meglumine Drugs 0.000 claims description 24
- 238000006243 chemical reaction Methods 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 239000002516 radical scavenger Substances 0.000 claims description 19
- 239000007790 solid phase Substances 0.000 claims description 17
- 229910021645 metal ion Inorganic materials 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 238000004659 sterilization and disinfection Methods 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- NBZBKCUXIYYUSX-UHFFFAOYSA-N iminodiacetic acid Chemical compound OC(=O)CNCC(O)=O NBZBKCUXIYYUSX-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- 230000000536 complexating effect Effects 0.000 claims description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 2
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 2
- 229910001424 calcium ion Inorganic materials 0.000 claims description 2
- 230000002950 deficient Effects 0.000 claims description 2
- 238000007865 diluting Methods 0.000 claims description 2
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 2
- 229910021644 lanthanide ion Inorganic materials 0.000 claims 1
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 abstract description 12
- 229940075613 gadolinium oxide Drugs 0.000 abstract description 10
- 229910001938 gadolinium oxide Inorganic materials 0.000 abstract description 10
- 238000002360 preparation method Methods 0.000 abstract description 8
- 239000002244 precipitate Substances 0.000 abstract description 3
- 239000013522 chelant Substances 0.000 description 19
- 229920005989 resin Polymers 0.000 description 19
- 239000011347 resin Substances 0.000 description 19
- 229910052747 lanthanoid Inorganic materials 0.000 description 17
- 150000002602 lanthanoids Chemical class 0.000 description 15
- 229910052751 metal Inorganic materials 0.000 description 15
- 239000002184 metal Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000010668 complexation reaction Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000002872 contrast media Substances 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- RYHQMKVRYNEBNJ-BMWGJIJESA-K gadoterate meglumine Chemical compound [Gd+3].CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 RYHQMKVRYNEBNJ-BMWGJIJESA-K 0.000 description 4
- 238000011194 good manufacturing practice Methods 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 3
- 238000002354 inductively-coupled plasma atomic emission spectroscopy Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 238000013353 HPLC-CAD method Methods 0.000 description 2
- 229920002536 Scavenger resin Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003729 cation exchange resin Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- VIFBVOSDYUIKIK-UHFFFAOYSA-J sodium;gadolinium(3+);2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate Chemical compound [Na+].[Gd+3].[O-]C(=O)CN1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 VIFBVOSDYUIKIK-UHFFFAOYSA-J 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- QBPPRVHXOZRESW-UHFFFAOYSA-N 1,4,7,10-tetraazacyclododecane Chemical compound C1CNCCNCCNCCN1 QBPPRVHXOZRESW-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 150000000921 Gadolinium Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- MFRUIHKAWNBCOS-UHFFFAOYSA-N OC1=C(C(=CC2=CC(=CC(=C12)O)S(=O)(=O)O)S(=O)(=O)O)N=NC=1C=C(C=CC=1[As](O)(=O)O)C1=CC(=C(C=C1)[As](O)(=O)O)N=NC1=C(C2=C(C=C(C=C2C=C1S(=O)(=O)O)S(=O)(=O)O)O)O Chemical compound OC1=C(C(=CC2=CC(=CC(=C12)O)S(=O)(=O)O)S(=O)(=O)O)N=NC=1C=C(C=CC=1[As](O)(=O)O)C1=CC(=C(C=C1)[As](O)(=O)O)N=NC1=C(C2=C(C=C(C=C2C=C1S(=O)(=O)O)S(=O)(=O)O)O)O MFRUIHKAWNBCOS-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 150000004697 chelate complex Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000010102 embolization Effects 0.000 description 1
- 230000005294 ferromagnetic effect Effects 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 238000010949 in-process test method Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 229960003330 pentetic acid Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
- A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
Landscapes
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
b)大環状キレートとランタニドとの錯体、遊離大環状キレートであって賦形剤X[X’,L](式中、Lは大環状キレートであり、X及びX’は金属イオンであり、特にカルシウム、ナトリウム、亜鉛及びマグネシウムから独立に選択される。)の形態ではないもの、及び遊離ランタニドを含む液体医薬組成物を、遊離大環状キレートの溶液と遊離ランタニドの溶液を混合して、大環状キレートによるランタニドの錯体を形成することによって調製して、大環状キレートによるランタニドの錯化を得るステップであって、遊離大環状キレートの量及び遊離ランタニドの量が、すべてのランタニドが錯化されるような量ではないステップと、
c)ステップb)で得られた医薬製剤中の遊離ランタニドの濃度Clan lを測定するステップであって、遊離大環状キレートの濃度Cch lが0に等しいステップと、
d)ステップb)で得られた製剤に、まず遊離ランタニドの錯化を完了してClan l=0とし、次にCch l=Ct ch l(Ct ch lは最終液体医薬製剤における遊離大環状キレートの目標濃度であり、0.002%〜0.4%mol/molの範囲内で選択される。)とするのに必要な量の遊離大環状キレートを添加することにより、Cch l及びClan lを調整するステップと
を含んでおり、最終液体医薬製剤中の遊離大環状キレートの量は、最終液体医薬製剤中の錯化大環状キレートの量に対する遊離大環状キレートの割合に対応する。
(i)以下の(a)〜(c)のいずれかの反応:
(a)DOTAとメグルミンの1:1モル比の水溶液と過剰のGd2O3との反応であって、すべてのDOTAが反応してGd−DOTAを生じる反応、又は
(b)pH2.0〜6.0におけるDOTAの水溶液と不足量のGd2O3との反応であって、すべてのガドリニウムが反応してGd−DOTAを生じ、次いでメグルミンを添加してpHを6.5〜8.0に上昇させ、次いで過剰のGd2O3を添加する反応、又は
(c)pH6.5〜8.0におけるDOTAの水溶液と過剰のメグルミン、過剰のGd2O3との反応であって、すべてのDOTAが反応してGd−DOTAを生じる反応
であって、(a)、(b)又は(c)が、過剰の未溶解Gd2O3を含有するGd−DOTAの第1の溶液を生じるステップと、
(ii)ステップ(i)で得られた第1の溶液を濾過して過剰の未溶解Gd2O3を除去し、過剰のGd2O3を含まないGd−DOTAを含む第2の溶液を得るステップと、
(iii)ステップ(ii)の第2の溶液に対して0.002〜0.4mol/mol%の未錯化形DOTAを添加して、液体医薬製剤を得るステップと
を含んでおり、未錯化形DOTAは配位金属イオンを含まない。
第1の態様の方法では、ステップ(i)の(a)、(b)及び(c)におけるGd2O3の過剰量は、0.001〜5mol/mol%、さらに好ましくは0.01〜1mol/mol%、最も好ましくは0.05〜0.5mol/mol%である。
(a)濾液を、固相結合スカベンジャーキレート剤と1回以上接触させて、溶液中の過剰のGd3+をスカベンジャーキレート剤と錯化させるステップと、
(b)ステップ(a)の濾液から固相を分離するステップと
によって、溶液中の過剰のGd3+を除去するステップをさらに含む。
(a)第1の態様の方法を実施して、第1の態様に記載の液体医薬製剤を得るステップと、
(b)適宜、ステップ(a)の液体医薬製剤を生体適合性担体で希釈するステップと、
(c)ステップ(b)の製剤を薬学的に許容される容器又はシリンジに分注して、分注容器又はシリンジを得るステップと、
(d)ステップ(a)〜(c)を無菌製造条件下で実施するか、或いはステップ(c)の分注容器又はシリンジの最終滅菌を実施して、薬学的に許容される容器又はシリンジ内の哺乳類への投与に適した形態のMRI造影剤を得るステップと
を含む方法を提供する。
DOTA:1,4,7,10−テトラアザシクロドデカン−1,4,7,10−四酢酸
DTPA:ジエチレントリアミン五酢酸
EDTA:エチレンジアミン四酢酸
GMP:適正製造規範(Good Manufacturing Practice)
HPLC:高性能液体クロマトグラフィー
HPLC−CAD:HPLC荷電化粒子検出器
ICP−AES:誘導結合プラズマ原子発光分光法
ICP−MS:誘導結合プラズマ質量分析法
MeCN:アセトニトリル
Min:分
MRI:磁気共鳴イメージング
WFI:注射用水。
焼結ガラスフィルター上のChelex−100樹脂(Sigma−Aldrich社製;100g)を1M HCl(1L)で4回に分けて4時間処理した。次いで溶出液がpH6.5になるまで樹脂を水洗し、水(400mL)中のメグルミン(10g)の溶液を樹脂と1時間平衡化させた。pH8になるまで樹脂を再度水洗し、濾過して1分間真空乾燥して湿性樹脂を得て、その形態(「Meg−Chelex」)で使用した。
検出器:ESA Corona荷電化粒子検出器;
カラム:SeQuant ZIC−pHILIC(5μm、150×4.6mm)。
移動相:100mM酢酸アンモニウム(A)、アセトニトリル(B)。
メグルミン(0.749g、4.00mmol)、DOTA(1.615g 4.00mmol)、酸化ガドリニウム(0.749g 2.04mmol)及び水(8.0g)をフラスコ内で混合し、60℃で一晩撹拌した。
Claims (10)
- Gd−DOTA金属錯体のメグルミン塩を、Gd−DOTA錯体の0.002〜0.4mol/mol%量の未錯化形DOTAと共に含む液体医薬製剤の調製方法であって、
(i)以下の(a)〜(c)のいずれかの反応:
(a)DOTAとメグルミンの1:1モル比の水溶液と過剰のGd2O3との反応であって、すべてのDOTAが反応してGd−DOTAを生じる反応、又は
(b)pH2.0〜6.0におけるDOTAの水溶液と不足量のGd2O3との反応であって、すべてのガドリニウムが反応してGd−DOTAを生じ、次いでメグルミンを添加してpHを6.5〜8.0に上昇させ、次いで過剰のGd2O3を添加する反応、又は
(c)pH6.5〜8.0におけるDOTAの水溶液と過剰のメグルミン、過剰のGd2O3との反応であって、すべてのDOTAが反応してGd−DOTAを生じる反応
であって、(a)、(b)又は(c)が、過剰の未溶解Gd2O3を含有するGd−DOTAの第1の溶液を生じるステップと、
(ii)ステップ(i)で得られた第1の溶液を濾過して過剰の未溶解Gd2O3を除去し、過剰のGd2O3を含まないGd−DOTAを含む第2の溶液を得るステップと、
(iii)ステップ(ii)の第2の溶液に対して0.002〜0.4mol/mol%の未錯化形DOTAを添加して、液体医薬製剤を得るステップと
を含んでおり、未錯化形DOTAが配位金属イオンを含まない、方法。 - ステップ(i)(a)(b)(c)のGd2O3の過剰量が0.05〜5mol/mol%である、請求項1に記載の方法。
- ステップ(iii)の未錯化形DOTAが、0.025〜0.25mol/mol%量である、請求項1又は請求項2に記載の方法。
- 未錯化形DOTAが、ランタニドイオン、カルシウムイオン、ナトリウムイオン、亜鉛イオン及びマグネシウムイオンを含まない、請求項1乃至請求項3のいずれか1項に記載の方法。
- ステップ(ii)が、濾過後に、
(a)濾液を、固相結合スカベンジャーキレート剤と1回以上接触させて、溶液中の過剰のGd3+をスカベンジャーキレート剤と錯化させるステップと、
(b)ステップ(a)の濾液から固相を分離するステップと
によって、溶液中の過剰のGd3+を除去するステップをさらに含む、請求項1乃至請求項4のいずれか1項に記載の方法。 - 固相結合スカベンジャーキレート剤が、スカベンジャーキレート剤のメグルミン塩として存在する、請求項5に記載の方法。
- スカベンジャーキレート剤がイミノ二酢酸を含む、請求項5又は請求項6に記載の方法。
- ステップ(i)(a)又は(b)のガドリニウム錯形成反応が50〜80℃で実施される、請求項1乃至請求項7のいずれか1項に記載の方法。
- MRI造影剤の調製方法であって、
(a)請求項1乃至請求項8のいずれか1項に記載の方法を実施して、請求項1乃至請求項8のいずれか1項に記載の液体医薬製剤を得るステップと、
(b)適宜、ステップ(a)の液体医薬製剤を生体適合性媒体で希釈するステップと、
(c)ステップ(b)の製剤を薬学的に許容される容器又はシリンジに分注して、分注容器又はシリンジを得るステップと、
(d)ステップ(a)〜(c)を無菌製造条件下で実施するか、或いはステップ(c)の分注容器又はシリンジの最終滅菌を実施して、薬学的に許容される容器又はシリンジ内の哺乳類への投与に適した形態のMRI造影剤を得るステップと
を含む方法。 - 最終滅菌が用いられる、請求項9に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1421163.5 | 2014-11-28 | ||
GBGB1421163.5A GB201421163D0 (en) | 2014-11-28 | 2014-11-28 | Formulations of metal complexes |
PCT/EP2015/077961 WO2016083600A1 (en) | 2014-11-28 | 2015-11-27 | Formulations comprising a meglumine salt of the metal complex gd-dota |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017535583A true JP2017535583A (ja) | 2017-11-30 |
JP6655617B2 JP6655617B2 (ja) | 2020-02-26 |
Family
ID=52349618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017528110A Active JP6655617B2 (ja) | 2014-11-28 | 2015-11-27 | Gd−DOTA金属錯体のメグルミン塩を含む製剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10314927B2 (ja) |
EP (1) | EP3223863B1 (ja) |
JP (1) | JP6655617B2 (ja) |
KR (1) | KR102457423B1 (ja) |
CN (1) | CN106999615B (ja) |
AU (1) | AU2015352421B2 (ja) |
CA (1) | CA2967876C (ja) |
GB (1) | GB201421163D0 (ja) |
WO (1) | WO2016083600A1 (ja) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201421163D0 (en) | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Formulations of metal complexes |
WO2018069179A1 (en) * | 2016-10-12 | 2018-04-19 | T2Pharma Gmbh | Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates |
WO2018069176A1 (en) * | 2016-10-12 | 2018-04-19 | T2Pharma Gmbh | Method of preparing formulations of lanthanide metal complexes of macrocyclic chelates |
EP3789044A1 (de) * | 2016-10-28 | 2021-03-10 | B.E. Imaging GmbH | Verfahren zur herstellung von pharmazeutischen formulierungen enthaltend chelatkomplexe von gadolinium mit reduziertem gehalt an toxischen verunreinigungen |
GB201703227D0 (en) * | 2017-01-20 | 2017-04-12 | Ge Healthcare As | Plastic containers |
WO2019020662A1 (de) * | 2017-07-27 | 2019-01-31 | Sanochemia Pharmazeutika Ag | Zubereitung enthaltend ein kontrastmittel, und verfahren zum herstellen |
AT521001B1 (de) * | 2018-02-23 | 2020-10-15 | Sanochemia Pharmazeutika Ag | Herstellungsverfahren für ein Kontrastmittel |
CN113527222B (zh) * | 2020-04-21 | 2023-06-13 | 威智医药股份有限公司 | 一种钆特酸葡甲胺的制备方法 |
IL298961A (en) | 2020-06-10 | 2023-02-01 | Justesa Imagen S A U | A process for obtaining high-purity meglumine gadotrate methotrexate (DOTA) and its use for the preparation of injectable galenic formulations |
CN118320137A (zh) * | 2020-07-13 | 2024-07-12 | 山东威智百科药业有限公司 | 一种钆特酸葡甲胺注射液及其制备方法 |
CN113801071B (zh) * | 2021-09-14 | 2023-04-07 | 安徽普利药业有限公司 | 一种钆特酸葡甲胺的精制方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5527688A (en) * | 1994-04-08 | 1996-06-18 | Pierce Chemical Company | Rapid assays for protein kinase activity |
IT1304501B1 (it) * | 1998-12-23 | 2001-03-19 | Bracco Spa | Uso di derivati di acidi biliari coniugati con complessi metallicicome "blood pool agents" per l'indagine diagnostica tramite risonanza |
US20090208421A1 (en) * | 2008-02-19 | 2009-08-20 | Dominique Meyer | Process for preparing a pharmaceutical formulation of contrast agents |
CN104955822B (zh) | 2013-01-28 | 2018-03-13 | T2医药有限责任公司 | 制备1,4,7,10‑四氮杂环十二烷‑1,4,7,10‑四乙酸及其络合物的方法 |
GB201421163D0 (en) | 2014-11-28 | 2015-01-14 | Ge Healthcare As | Formulations of metal complexes |
-
2014
- 2014-11-28 GB GBGB1421163.5A patent/GB201421163D0/en not_active Ceased
-
2015
- 2015-11-27 JP JP2017528110A patent/JP6655617B2/ja active Active
- 2015-11-27 CA CA2967876A patent/CA2967876C/en active Active
- 2015-11-27 US US15/531,430 patent/US10314927B2/en active Active
- 2015-11-27 CN CN201580064548.5A patent/CN106999615B/zh active Active
- 2015-11-27 KR KR1020177014035A patent/KR102457423B1/ko active IP Right Grant
- 2015-11-27 WO PCT/EP2015/077961 patent/WO2016083600A1/en active Application Filing
- 2015-11-27 AU AU2015352421A patent/AU2015352421B2/en active Active
- 2015-11-27 EP EP15801443.1A patent/EP3223863B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN106999615A (zh) | 2017-08-01 |
US20170258944A1 (en) | 2017-09-14 |
WO2016083600A1 (en) | 2016-06-02 |
EP3223863B1 (en) | 2019-02-06 |
CA2967876A1 (en) | 2016-06-02 |
CN106999615B (zh) | 2020-11-17 |
AU2015352421A1 (en) | 2017-05-18 |
AU2015352421B2 (en) | 2021-07-15 |
EP3223863A1 (en) | 2017-10-04 |
CA2967876C (en) | 2022-09-20 |
JP6655617B2 (ja) | 2020-02-26 |
KR20170088854A (ko) | 2017-08-02 |
US10314927B2 (en) | 2019-06-11 |
GB201421163D0 (en) | 2015-01-14 |
KR102457423B1 (ko) | 2022-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6655617B2 (ja) | Gd−DOTA金属錯体のメグルミン塩を含む製剤 | |
JP6709216B2 (ja) | 金属錯体製剤 | |
JP6846347B2 (ja) | ランタニド錯体製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181122 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20190607 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190723 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190724 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20191021 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191223 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200114 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200203 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6655617 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |